Tracers / [99mTc]Tc(CO)3-GRGDHV

[99mTc]Tc(CO)3-GRGDHV

Also written as [Tc-99m]Tc(CO)3-GRGDHV

Radionuclide: Tc-99m t½ 360.6 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

Glioma and brain tumours Preclinical only, no clinical indication yet

What it is

Compound class: RGD peptide (GRGDHV) labeled with technetium-99m tricarbonyl complex
Target / mechanism: αvβ3 integrin PMID 35215229
Clinical application: —
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	HPLC	98.30 ± 0.17%	>94%	GRGDHV	35215229 2022 Pharmaceuticals (Basel) Peptides were synthesized manually employing the classical Fmoc-chemistry methodology — Chromatographic yields of 96.70 ± 0.72% and 98.30 ± 0.17% were obtained for [131I]I-GRGDYV (Figure 3B) and [99mTc]Tc(CO)3-GRGDHV (Figure 3D), respectively

Need this precursor?We can point you to suppliers for [99mTc]Tc(CO)3-GRGDHV, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 35215229. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 35215229: 'GRGDHV'.